Patient pain during intravitreal injections under topical anesthesia: a systematic review

Helio Francisco Shiroma1*, Augusto Key Karazawa Takaschima2, Michel Eid Farah1, Ana Luisa Höfling-Lima1, Graziela de Luca Canto3, Roberto Henrique Benedetti4 and Eduardo Buchele Rodrigues1

Abstract

Background: Intravitreal injection (IVI) is a very common vitreoretinal procedure, and multiple injections are often required per patient. This systematic review was conducted to evaluate the effectiveness of various local anesthetic techniques in reducing pain during injection.

Methods: A systematic review was conducted based on searches of Cochrane, LILACS, PubMed, Scopus, Web of Science, and the gray literature (Google Scholar). The end search date was February 19, 2016, across all databases. We classified pain by converting visual analog scale (VAS) scores (0–100 mm) into Jensen’s classification levels: 0–4, no pain; 5–44, mild pain; 45–74, moderate pain; and 75–100, severe pain. An intervention was considered clinically significant when pain score change was >12 mm on a 100-mm scale.

Results: Eight studies out of 23 met the eligibility criteria. The total number of patients was 847. Most studies (5/8 [62.5%]) were at unclear risk of bias because of unclear randomization, thus providing only moderate evidence to this review. The anesthetic techniques included eye drops with proparacaine, tetracaine or cocaine, a lidocaine pledget or gel, and subconjunctival injection of 2% lidocaine or 0.75% levobupivacaine. No study comprised all of the techniques. Pain was mild (VAS scores, 5–44 mm) regardless of anesthetic technique. A clinically significant intervention (pain score change >12 mm) was found for only one study comparing proparacaine drops, lidocaine gel, and subconjunctival lidocaine; in that study, a subconjunctival injection of 2% lidocaine provided the greatest pain reduction. A meta-analysis was not possible due to study heterogeneity.

Conclusions: Patient pain during IVI under topical anesthesia is mild regardless of anesthetic technique. A subconjunctival injection of 2% lidocaine could be an option for highly sensitive patients. However, with moderate level of evidence, no single anesthetic technique could be defined as the best option for IVI.

Background

Intravitreal injection (IVI) is one of the most common vitreoretinal procedures performed nowadays [1]. Steroids, antibiotics, and antiviral drugs have been injected into the vitreous humor for many years, but the use of IVI has increased dramatically only recently after the introduction of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration [2]. Other indications for IVI of anti-VEGF include diabetic retinopathy, vascular occlusions, and cystoid macular edema [3].

Patients may experience pain during IVI [3], especially if multiple injections are required. The use of local anesthetics minimizes pain and avoids intraocular complications caused by pain-induced rapid, uncontrolled movements of the eye [4]. Based on recent surveys, most ophthalmologists (65–90%) perform IVI using local anesthetic eye drops [5]. Other techniques include the use of an anesthetic gel, peribulbar block, subconjunctival injection, and a pledget soaked in anesthetic [3]. However, there is no consensus on the best anesthetic option [6].

The choice of a single anesthetic technique for IVI requires careful evaluation of patient pain, ideally using...
an objective measure [7]. However, patient pain is typically evaluated using one-dimensional tools such as numeric rating or visual analog scales [8]. Such type of scales raises concerns of bias [9].

To our knowledge, no systematic review has addressed patient pain during IVI under topical anesthesia. The aim of this systematic review was to evaluate the effectiveness of different local anesthetic techniques for IVI within the limitations of analog (visual or oral) pain scales.

Methods
This systematic review was written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [10].

Protocol and registration
The systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO) under number CRD42016037099.

Terminology
For this systematic review, we compared different techniques of local anesthesia for IVI of antiangiogenic agents and steroids. Antiangiogenic agents included bevacizumab (Avastin®; Genentech/Roche, USA), ranibizumab (Lucentis®; Novartis, Switzerland), and aflibercept (Eylea®; Bayer HealthCare, Germany). Steroids included biodegradable dexamethasone implant of sustained release and triamcinolone. Local anesthetics included eye drop anesthetics (tetracaine, proparacaine, and cocaine), lidocaine gel, lidocaine pledget, subconjunctival anesthesia, and peribulbar block. Anesthetic and/or analgesic effect was evaluated using analogue (visual or oral) pain scales with grades ranging from 0 to 100 mm or from 0 to 10 cm.

Study design
The aim of this systematic review was to evaluate the effectiveness of different local anesthetic techniques for IVI of anti-VEFG agents and steroids within the limitations of analogue pain scales. Studies were selected in two steps. First, we classified patient-reported pain scores for each anesthetic technique covered by individual studies. Scales ranging from 0 to 10 cm or points were converted to a range from 0 to 100 mm. Other scales were not included in this review, due to heterogeneity. We classified pain by converting visual analog scale (VAS) scores (0–100 mm) into Jensen’s classification levels [8]: 0–4, no pain; 5–44, mild pain; 45–74, moderate pain; and 75–100, severe pain. Second, we considered that an intervention was clinically significant when pain score change was >12 mm on a 100-mm scale. The relative value difference with clinical significance in patient perception comparing different treatments for pain varies from 9 to 15 mm in a 0 to 100 mm scale [9, 11], but higher values have been reported [12]. For a conservative approach, we chose the average value of 12 mm, which we think reflects a clinically meaningful difference in pain perception.

Information sources
Studies to be considered for inclusion were identified by searching the following electronic bibliographic databases: Cochrane, LILACS, PubMed, Scopus, and Web of Science. An additional search of the gray literature was performed using Google Scholar. The end search date was February 19, 2016, across all databases. In addition, the reference lists of the selected articles were searched manually.

Appropriate truncation and word combinations were selected and adapted for each database search (Additional file 1: Table S1), with the aid of a health sciences librarian. All references were run through the reference manager software Mendeley® (Elsevier), and duplicate hits were removed.

Study selection and eligibility criteria
We reviewed studies whose objective was to compare the effect of different local anesthetic techniques for IVI of antiangiogenic agents and steroids using an analog (visual or oral) pain scale ranging from 0 to 100 (or 0–10).

There were two phases of review. In phase 1, we reviewed titles and abstracts and excluded the following: (1) studies conducted in infants (0–18 years); and (2) reviews, letters, conference abstracts, and editorials. In phase 2, we reviewed full-text articles and additionally excluded the following: (3) studies including sedation or general anesthetics for IVI; (4) studies including IVI of medications other than antiangiogenic agents or steroids; (5) non-randomized clinical trials; (6) studies using a pain scale other than an analogue (visual or oral) scale ranging from 0 to 100 or 0 to 10; (7) studies not evaluating pain at the moment of injection; and (8) studies not using mean as the measure of central tendency for pain score.

Two authors (HS, AT) independently reviewed all search results. In both phases, when disagreements emerged between the two reviewers, they tried to reach a consensus. When they were unable to reach a consensus, a third author (GLC) made the final decision. Articles that did not appear to meet the inclusion criteria were discarded. In phase 2, the same authors reviewed the full-text of the articles. The third author (GLC) read the abstracts of all the selected articles and made the final decision on inclusion; however, final selection was always based on the full text of the publication. The reference
lists of selected studies were critically assessed by both HS and AT.

Data collection
One author (HS) collected data from the selected studies. The following information was recorded: study background (authors, year, country, study design, and objective), population characteristics (number of patients, mean age), interventions (anesthetic techniques, type of medication, and pain grading), and outcomes (average pain score at the moment of injection and main conclusion). A second author (AT) crosschecked all the collected information and confirmed its accuracy. Again, any disagreement was resolved by discussion and mutual agreement among the three reviewers (HS, AT, LC).

Risk of bias in individual studies
The methodology of the selected studies was evaluated using the Cochrane Collaboration’s risk of bias tool [13]. The following characteristics were included in the assessment: sequence generation, allocation concealment, blinding of participants and personnel, potential threats to validity of performance, blinding of outcome assessment, and potential threats to validity of detection of bias [13]. Two reviewers (HS, AT) independently assessed the quality of each included study. Disagreements between the reviewers were resolved through discussion.

Outcome measures
The main outcome measure was the evaluation of the anesthetic/analgesic effect of different anesthetic techniques for IVI using analog (verbal or visual) pain scales.

Synthesis of results and risk of bias across studies
If feasible, the possibility of meta-analysis and risk of bias across studies was considered.

Results
Study selection
During the initial search (phase 1) and following duplicate removal, 374 different citations were identified across the five electronic databases. An additional search using Google Scholar found no additional relevant articles. After a comprehensive evaluation of the abstracts, 23 articles were deemed potentially relevant and were selected for phase 2. Of these 23 studies selected in the first evaluation, two studies using biodegradable dexamethasone implant included. However, those two studies were excluded, because they were not randomized. Others 13 were excluded (Additional file 2: Table S2). Thus, only eight studies were retained for the final selection. A flowchart of the process of literature search and selection is shown in Fig. 1.

Study characteristics
A summary of the study characteristics is shown in Table 1. The selected studies were conducted in Brazil [1, 6], Canada [11], Turkey [14], UK [15], and USA [2, 5, 16] from 2008 to 2015. The total number of patients for all studies was 847. The injected medications were ranibizumab, bevacizumab, and triamcinolone.

Risk of bias within studies
Selection biases were evaluated through random sequence generation and allocation concealment. We judged only three (37.5%) of the eight studies to be at low risk of bias based on random sequence generation and allocation concealment; the other studies were considered to be at unclear risk of bias because of unclear randomization process, thus providing moderate level of evidence to this review. We present other potential sources of bias as percentages in Fig. 2 and per study in Fig. 3.

Characteristics of included studies
The characteristics of the eight studies evaluating the effect of different local anesthetic techniques for IVI of antiangiogenic agents and steroids using analog (visual or oral) pain scales are summarized in Table 1.

Anesthetic methods
Different anesthetics methods were recorded and compared among the included studies. The described techniques included eye drops with proparacaine [2, 5, 6, 14–16] and tetracaine [5, 11, 16], 4% lidocaine pledgets [11], 4% cocaine + epinephrine 1/100,000 drops [11], subconjunctival injection of 2% lidocaine [6, 15], lidocaine gel at 2, 3.5, 5, 8 and 12% [1, 2, 6], and 0.75% levobupivacaine [14].

Classification of studies according to pain
We classified pain by converting (VAS) scores (0–100 mm) into Jensen’s classification levels [8]: 0–4, no pain; 5–44, mild pain; 45–74, moderate pain; and 75–100, severe pain. Only six studies evaluated pain at the moment of IVI [1, 2, 5, 6, 11, 14]. On the other hand, Blaha et al. [16] and Kumar et al. [15] considered a combined score calculated by adding the discomfort for anesthesia and the IVI.

Patient pain was mild in all studies regardless of anesthetic technique or definition of pain scores (single or combined) (Table 2). A meta-analysis was not possible due to high study heterogeneity.

Clinically meaningful difference in pain scores
Pain scores reflecting clinically significant anesthetic techniques for IVI are shown in Table 2. Three studies [5,
6, 14] showed a statistically significant difference in pain scores between different anesthetic techniques. However, only one study [6] presented a clinically significant pain score change of at least 12 mm in a 100 mm scale. Andrade et al. [6] compared the anesthetic effectiveness of topical proparacaine drops alone, proparacaine + subconjunctival injection of 2% lidocaine, and 2% lidocaine gel in 92 patients. A subconjunctival
### Table 1 Summary of characteristics of the included studies

| Study background | Participants | Interventions | Outcomes |
|------------------|--------------|---------------|----------|
| **References (country) Objective** | **Cases, n** | **Mean age, years** | **Groups according to anesthetic technique** | **Pain grading** | **Drug** | **Average pain score** | **Main conclusion** |
| Blaha et al. [16] (USA) To compare pain scores during injection versus total procedure for four anesthetic techniques | 96 | 80 | G1: 0.5% topical proparacaine | Pain was graded on a 0 to 10 scale | RNZ, BVZ | G1: 3.0 | No statistical difference in pain scores for the four anesthetic techniques. Topical drops provided excellent anesthesia in a quick, comfortable, and safe manner for IVI |
| | | | G2: 0.5% topical tetracaine | | | G2: 2.8 | |
| | | | G3: topical proparacaine + 4% lidocaine pledget | | | G3: 2.3 | |
| | | | G4: topical proparacaine + SC injection of 2% lidocaine | | | G4: 3.1 | |
| | | | | | | \( p = 0.28 \) | |
| Yau et al. [11] (Canada) To compare the anesthetic effectiveness of three topical agents used for IVIs | 93 | Group 1: 83.6 | G1: 0.5% tetracaine hydrochloride drops + 4% lidocaine pledget for 10 | Patients graded pain on a 100-mm VAS, or by saying a number from 0 to 100 | RNZ | G1: 19 (12–26) | No clinical (statistical) difference in patient pain between the three topical agents tested. The addition of a 4% lidocaine pledget for 10” offered no clinical advantage in pain relief compared to 0.5% tetracaine or 4% cocaine drops alone |
| | | Group 2: 79.5 | G2: 0.5% tetracaine hydrochloride drops | | | G2: 21 (13–29) | |
| | | Group 3: 82.1 | G3: 4% cocaine + epi-nephrine 1/100,000 drops | | | G3: 21 (16–27) | |
| Örnek et al. [14] (Turkey) To compare the efficacy of topical 0.75% levo-bupivacaine and 0.5% proparacaine | 96 | 63.97 | G1: 0.75% levobupivacaine drops | Patients graded pain on a 100-mm VAS | RNZ, TAC | G1: 44.77 ± 16.42 | 0.5% topical proparacaine was more effective than 0.75% topical levobupivacaine in preventing pain during IVI |
| | | | G2: 0.5% proparacaine drops | | | G2: 34.18 ± 14.83 | \( p = 0.003 \) |
| Shiroma et al. [1] (Brazil) To investigate the safety and anesthetic efficacy of five concentrations of lidocaine gel | 260 | 70.1 | G1: 2% lidocaine gel | Patients graded pain on a 0 to 10 scale | RNZ | G1: 2.63 ± 1.68 | Lidocaine gel at concentrations from 2% to 12% induced similar anesthetic effect for IVI |
| | | | G2: 3.5% lidocaine gel | | | G2: 2.08 ± 1.35 | |
| | | | G3: 5% lidocaine gel | | | G3: 2.00 ± 1.65 | |
| | | | G4: 8% lidocaine gel | | | G4: 1.93 ± 1.40 | |
| | | | G5: 12% lidocaine gel | | | G5: 1.83 ± 1.35 | \( p = 0.077 \) |
| Andrade et al. [8] (Brazil) To compare the anesthetic effectiveness of topical proparacaine drops, SC lidocaine, and 2% lidocaine gel | 92 | 66.4 | G1: proparacaine | Patients graded pain on a 0 to 10 scale | BVZ | G1: 3.2 ± 1.7 | SC injection of lidocaine was most effective in preventing pain during IVI compared to proparacaine or 2% lidocaine gel |
| | | | G2: proparacaine + SC injection of 2% lidocaine | | | G2: 1.0 ± 1.0 | |
| | | | G3: 2% lidocaine gel | | | G3: 1.0 ± 1.1 | |
Table 1 continued

| Study background | Participants | Interventions | Outcomes |
|------------------|--------------|---------------|----------|
| **References (country)** | **Objective** | **Cases, n** | **Mean age, years** | **Groups according to anesthetic technique** | **Pain grading** | **Drug** | **Average pain score** | **Main conclusion** |
| Kumar et al. [15] (UK) | To compare patient comfort during IVI after SC anesthesia or topical eye drops | 30 | 72 | G1: 0.5% proxymetacaine | Patients graded pain on a 0 to 10 scale | TAC | G1: 0.87 ± 0.83 | There was no significant difference in pain scores or overall satisfaction scores between the two groups |
| | | | | G2: SC injection of 2% lidocaine | | | G2: 0.93 ± 0.96 p = 0.84 |
| Davis et al. [2] (USA) | To compare the anesthetic effect among topical proparacaine drops, 4% lidocaine solution, and 3.5% lidocaine gel | 120 | 80.18 | G1: 0.5% topical proparacaine | Patients graded pain on a 0 to 10 scale | BVZ, RNZ, TAC | G1: 1.78 ± 1.44 | There was no significant difference in pain scores or overall satisfaction scores between the different groups |
| | | | | G2: topical proparacaine + 4% lidocaine pledget | | | G2: 1.75 ± 1.46 |
| | | | | G3: 3.5% lidocaine gel | | | G3: 1.48 ± 1.58 p = 0.38 |
| Rifkin and Schaal [5] (USA) | To determine factors associated with patient comfort during in-office IVI | 60 | 65 | G1: 0.5% TetraVisc | Patients graded pain on a 0 to 10 scale | BVZ, RNZ, TAC | G1: 3.39 ± 2.26 | The tetracaine group reported the lowest pain |
| | | | | G2: proparacaine | | | G2: 3.17 ± 2.18 |
| | | | | G3: tetracaine | | | G3: 3.05 ± 2.01 p < 0.01 |

G group, IVI intravitreal injection, SC subconjunctival, RNZ ranibizumab, BVZ bevacizumab, AFL aflibercept, TAC triamcinolone acetonide
injection of 2% lidocaine was most effective in preventing pain compared with the two other groups. Difference in pain score between subconjunctival injection (10 mm) or lidocaine gel (10 mm) versus proparacaine (32 mm) was 22 mm. These differences were considered clinically meaningful.

Discussion

Our systematic review of the literature revealed mild pain in studies about IVI of antiangiogenic agents and steroids, regardless of anesthetic technique. With moderate level of evidence, no single anesthetic technique could be defined as the best option for IVI.

Comparison of anesthetic techniques requires the use of appropriate pain assessment tools [17]. Pain VAS and numerical rating scales (NRS) are considered reliable to evaluate the efficacy of anesthetic or analgesic treatments [8]. Some trials also use four-point verbal categorical pain scales (VRS) to assess discomfort, although VAS and NRS are considered superior to VRS [9]. VAS and NRS have similar sensitivity, and the choice between them is subjective. To provide a meaningful interpretation of pain scale scores, we converted pain scores into Jensen’s levels of pain [8]. All included studies presented mild discomfort during IVI, regardless of anesthetic technique. In this setting, even an effective treatment would show only a small change in pain intensity, and a comparison among anesthetic techniques would probably exhibit low sensitivity [17]. Of the eight included studies, three studies [5, 6, 14] showed a statistically significant difference in VAS or NRS pain scores between different anesthetic techniques. However, only one study [6] found a clinically significant pain score change of at least 12 mm in a 100 mm VAS or NRS scale. In that study, Andrade et al. [6] concluded that a subconjunctival injection of

Fig. 2 Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies (n=8)

Fig. 3 Risk of bias summary: review authors’ judgments about each risk of bias for each included study
Table 2 Pain in the included studies according to Jensen's classification [8]

| References (country) | Groups according to anesthetic method | Difference in pain | Mean pain score related to discomfort of anesthesia | Mean pain score during injection | Mean global pain | Jensen's classification |
|----------------------|---------------------------------------|--------------------|-----------------------------------------------------|-------------------------------|-----------------|------------------------|
| Blaha et al. [16] (USA) | G1: 0.5% topical proparacaine | NS                  | G1: 14                                             | G1: 30                         | G1: 44           | G1: MI                 |
|                      | G2: 0.5% topical tetracaine                  |                    | G2: 7                                              | G2: 28                         | G2: 35           | G2: MI                 |
|                      | G3: topical proparacaine + 4% lidocaine pledget |                    | G3: 16                                             | G3: 23                         | G3: 39           | G3: MI                 |
|                      | G4: topical proparacaine + SC injection of 2% lidocaine |                    | G4: 10, $p = 0.17$ (NS)                          | G4: 31, $p = 0.28$ (NS)        | G4: 41, $p = 0.65$ (NS) | G4: MI                 |
| Yau et al. [11] (Canada) | G1: 0.5% tetracaine hydrochloride drops + 4% lidocaine pledget for 10 | NS                  |                                                 |                               |                 |                        |
|                      | G2: 0.5% tetracaine hydrochloride drops                  |                    | G2: 7                                              | G2: 21                         |                 | G2: MI                 |
|                      | G3: 4% cocaine + epinephrine 1/100,000 drops                  |                    | G3: 21                                             | G3: 21                         |                 | G3: MI                 |
| Örnek et al. [14] (Turkey) | G1: 0.75% levobupivacaine drops                  | Statistical different, but not clinically significant | NA                                 | G1: 44.77                       | NA               | G1: MI                 |
|                      | G2: 0.5% proparacaine drops                  |                    | G2: 34.18, $p = 0.003$                             | G1: 44.77                       | NA               | G1: MI                 |
| Shiroma et al. [1] (Brazil) | G1: 2% lidocaine gel                  | NS                  | G1: 0                                              | G1: 26.3 ± 168                  | G1: 26.3         | G1: MI                 |
|                      | G2: 3.5% lidocaine gel                  |                    | G2: 0                                              | G2: 20.8 ± 135                  | G2: 20.8         | G2: MI                 |
|                      | G3: 5% lidocaine gel                  |                    | G3: 0                                              | G3: 200.0 ± 165                 | G3: 200.0        | G3: MI                 |
|                      | G4: 8% lidocaine gel                  |                    | G4: 0                                              | G4: 19.3 ± 140                  | G4: 19.3         | G4: MI                 |
|                      | G5: 12% lidocaine gel                  |                    | G5: 0                                              | G5: 18.3 ± 135                  | G5: 18.3         | G5: MI                 |
| Andrade et al. [6] (Brazil) | G1: proparacaine                      | SC injection of 2% lidocaine was most effective, with clinical significance (≥ 12 mm) | NA                                 | G1: 32.17                       | NA               | G1: MI                 |
|                      | G2: proparacaine + SC injection of 2% lidocaine                  |                    | G2: 10 ± 10                                       | G2: 10 ± 11, $p = 0.02$         |                 | G2: MI                 |
|                      | G3: 2% lidocaine gel                  |                    | G3: 10 ± 11                                       | G3: 10 ± 11, $p = 0.02$         |                 | G3: MI                 |
| Kumar et al. [15] (UK) | G1: 0.5% proximetacaine                | NS                  | G1: 6.0 ± 0.63                                     | G1: 8.7 ± 0.83                  | G1: 14.7         | G1: MI                 |
|                      | G2: SC injection of 2% lidocaine                  |                    | G2: 6.0 ± 0.96                                     | G2: 9.3 ± 0.96, $p = 0.84$      | G2: 15.3         | G2: MI                 |
| Davis et al. [2] (USA) | GA: 0.5% topical proparacaine                  | NS                  | NA                                                | G1: 17.8 ± 144                  | NA               | G1: MI                 |
|                      | GB: topical proparacaine + 4% lidocaine pledget                  |                    | G2: 17.5 ± 146                                     | G2: 17.5 ± 146                  |                 | G2: MI                 |
|                      | GC: 3.5% lidocaine gel                  |                    | G3: 14.8 ± 158, $p = 0.38$                        | G3: 14.8 ± 158                  |                 | G3: MI                 |
| Rifkin and Schaal [5] (USA) | G1: 0.5% TetraVisc                      | Statistical different, but not clinically significant | NA                                 | G1: 33.9 ± 226                  | NA               | G1: MI                 |
|                      | G2: proparacaine                  |                    | G2: 31.7 ± 21.8                                    | G2: 31.7 ± 21.8                  |                 | G2: MI                 |
|                      | G3: tetracaine                  |                    | G3: 30.5 ± 20.1                                    | G3: 30.5 ± 20.1                  |                 | G3: MI                 |

$G$ group, $MI$ mild, $S$ significant, $NS$ not significant, NA not available
2% lidocaine was most effective in preventing pain compared to lidocaine gel or proparacaine drops. However, Andrade et al. [6] did not describe the level of discomfort during IVI under subconjunctival anesthesia. Moreover, Kumar et al. [15] failed to observe similar benefits of the subconjunctival approach. The penetration and duration of gel is an important point in topical anesthesia. Lidocaine is absorbed extensively following mucosal intra-muscular, rectal, transdermal, and inhalation pathways [18], studies showed the anesthesia with lidocaine 3.5% gel was achieved within 5 min of application in 92% of the subjects [19].

Rodrigues et al. demonstrated that smaller gauge needles 30-G induced less pain than 26-G. In other study published by van Asten et al. comparing ultrathin 33-G needles or 30-G needle concluded that 33-G needle did not result in lower IVI pain (p = 0.758), but tended to cause less vitreal reflux (p = 0.054) and may limit scleral damage [20, 21].

Rifkin and Schaal published a study evaluating patients’ during intravitreal injection, under topical anesthesia, and observed factors that could influence pain: improved vision from previous injection, female sex, and age >65 years and number of injections, where pain scores decreased with each consecutive injection. [5] However, in a study published by Moisseiev et al., did not confirm these correlation. They also evaluated the injection site (quadrant), number of injections, presence of diabetes mellitus, and lens status. On analysis of injection location by quadrants, such a trend existed toward less pain in the inferonasal quadrant [22].

A meta-analysis was not considered feasible due to high study heterogeneity. This lack of homogeneity was related to the many different anesthetic techniques compared in each study. In addition, some authors combined the discomfort associated with the anesthetic procedure itself to the pain score, while others did not.

Surveys of retina specialists in different countries demonstrated a predominance of topical anesthetic eye drops for IVI [5, 23]. Indeed, in all studies included in this systematic review, proparacaine or tetracaine drops were used; eye drops were either combined with other types of anesthetics to relieve the discomfort caused by dilating drops or povidone iodine drops, or as a single anesthetic choice.

Although eye drops were effective in all selected studies, we could not define a single local anesthetic technique as the gold standard for IVI. Individual preferences, either from the ophthalmologist or the patient, should guide the choice of topical anesthesia. Perhaps, in patients with high sensitivity to pain, a subconjunctival injection of 2% lidocaine could be an option. Considering only pain scores, the low level of discomfort associated to the procedure makes comparing anesthetic techniques a challenge due to low sensitivity. Future studies should focus on side effects of drugs or patient rejection of a specific technique rather than preference.

One of the limitations of this systematic review is the heterogeneity of the included studies, with no synthesis of individual results. Ranking of pain scores according to Jensen’s classification is reliable even in the absence of a meta-analysis, but neither it derives from a statistical tool nor it generates a single median score for each technique. Nonetheless, only three of the included studies were judged to be at low risk of bias based on random sequence generation.

The aim of this review was to evaluate the effectiveness of different local anesthetic techniques for IVI. We considered the pain only at the moment of injection. Chemical keratitis could cause discomfort, even hours after the injection, caused by anesthetics or mydriatic drops, lidocaine gel or PVPI. It usually solved before the first post-operative day.

In conclusion, patient pain was mild in all studies regardless of anesthetic technique. With moderate level of evidence, no single anesthetic technique could be defined as the best option for IVI. Although complete pain relief was not attained, a subconjunctival injection of 2% lidocaine could be an option for highly sensitive patients. Mild pain suggests future studies should focus on side effects or rejection of a specific technique rather than preference.

Additional files

Additional file 1: Table S1. Database search strategy.
Additional file 2: Table S2. Excluded articles with reasons for exclusion.

Authors’ contributions
HS: collection of data, involved in drafting the manuscript, analysis and interpretation of data. Gave final approval of the version to be published. AT: involved in drafting the manuscript, contributions to acquisition, and interpretation of data. MF: Acquisition of funding, made substantial contributions to conception and design. RHB: involved in revising it critically for important intellectual content. GHC: contributions to acquisition, analysis and interpretation of data. RHB: contributions to analysis and interpretation of data. ERB: involved in drafting the manuscript and revising it critically for important intellectual content. General supervision. All authors read and approved the final manuscript.

Acknowledgements
The authors thank Gregory Blaha, MD for technical assistance during the preparation of this manuscript.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 14 January 2017    Accepted: 19 April 2017
Published online: 03 July 2017

References
1. Shiroma HF, Rodrigues EB, Farah ME, Penha FM, Lorenzo JC, Grumann A, et al. Safety and efficacy of various concentrations of topical lidocaine gel for intravitreal injection. Expert Opin Drug Saf. 2014;13(10):1299–303.
2. Davis MJ, Pollack JS, Shott S. Comparison of topical anesthetics for intravitreal injections: a randomized clinical trial. Retina. 2012;32(4):701–5.
3. Gambrell J, Schaal S. Topical anesthesia for intravitreal injection. Expert Opin Drug Deliv. 2012;9(7):731–3.
4. Tewari A, Shah GK, Dhalla MS, Blinder KJ. Surface anesthesia for office-based retinal procedures. Retin J Retin Vitr Dis. 2012;27(6):804–5.
5. Rifkin L, Schaal S. Factors affecting patients’ pain intensity during in office intravitreal injection procedure. Retin J Retin Vitr Dis. 2012;32(4):696–700.
6. Andrade GC, Carvalho AC, de Andrade GC, Maia de Carvalho AC, de Carvalho ACM. Comparison of 3 different anesthetic approaches for intravitreal injections: a prospective randomized trial. Arq Bras Oftalmol. 2015;78(1):27–31.
7. Dexter F, Chestnut DH. Analysis of statistical tests to compare visual analog scale measurements among groups. Anesthesiology. 1995;82(4):896–902.
8. Jensen MR, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407–14.
9. Breivik EK, Bjorhjorn GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16(1):22–8.
10. Mohr D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):356–41.
11. Yau GL, Jackman CS, Hooper PL, Sheidow TG. Intravitreal injection anesthesia—comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol. 2011;151(2):333–7.
12. Kersten P, White PJ, Tennant A. Is the pain visual analogue scale linear and responsive to change? An exploration using Rasch analysis. PLoS ONE. 2014;9(6):e99485.
13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
14. Örnek N, Apan A, Örnek K, Gunay F. Anesthetic effectiveness of topical levobupivacaine 0.75% versus topical proparacaine 0.5% for intravitreal injections. Saudi J Anaesth. 2014;8(2):198–201.
15. Kumar N, Dhir L, Jivan S, Prasad SD. Assessment of comfort during intravitreal injections and comparison of anaesthetic drops and subconjunctival anaesthesia. Asian J Ophthalmol. 2008;10(3):185–6.
16. Blaha GR, Tilton EP, Barouch FC, Marx JL. Randomized trial of anesthetic methods for intravitreal injections. Retina. 2011;31(3):533–9.
17. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.
18. Benowitz NO, Meister W. Clinical pharmacokinetics of lidocaine. Clin Pharmacokinet. 1978;3:177–201.
19. Busbee BG, Alam A, Reichel E. Lidocaine hydrochloride gel for ocular anesthesia: results of a prospective randomized study. Ophthalmic Surg Lasers Imaging. 2008;39(5):386–90.
20. Rodrigues EB, Grumann A Jr, Penha FM, et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther. 2011;27:197–203.
21. van Asten F, van Middendorp H, Verkerk S, Breukink MB, Lomme RM, Hovyng CB, Evers AW, Klevering BJ. Are intravitreal injections with ultrathin 33-G needles less painful than the commonly used 30-G needles? Retina. 2015;35(9):1778–85.
22. Moisseiev E, Regenberg M, Bartfeld Y, Barak A. Evaluation of pain in intravitreal bevacizumab injections. Eye. 2014;28(8):980–5.
23. Shiroma HF, Farah ME, Takahashi WY, Gomes AMV, Goldbaum M, Rodrigues EB. Survey: technique of performing intravitreal injection among members of the Brazilian Retina and Vitreous Society (SBRV). Arq Bras Oftalmol. 2015;78(1):32–5.